AVC-S-101 / Avidicure - LARVOL DELTA

Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer (GlobeNewswire) - "Avidicure...today announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures....We are eager to build a broad pipeline with our unique platform and progress our lead oncology product, AVC-S-101, into clinical development for solid tumors....Avidicure’s lead product, AVC-S-101, is a TROP2-targeting booster that is being developed for non-small cell lung cancer and multiple other indications....The company will be presenting preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting in April, and at the American Society of Clinical Oncology (ASCO) Annual Meeting in May."

Financing • Preclinical • Non Small Cell Lung Cancer